Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International StudyClinical Research Published on 2022-06-012024-09-04 Journal: Journal of the American Society of Nephrology [Category] 대상포진, [키워드] biologics children Hypogammaglobulinemia nephrotic syndrome neutropenia rituximab [DOI] 10.1681/ASN.2021111472 PMC 바로가기 [Article Type] Clinical Research
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases리툭시맙은 자가면역 질환에서 COVID-19 백신에 대한 B 세포 반응을 손상시키지만 T 세포 반응을 손상시키지 않습니다Article Published on 2022-06-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] absence activated anti-spike antibody response anti-Spike IgG Antibody Response Autoimmune disease autoimmune disease patient BNT162b2 CD4 CD8 CD8 T cell cellular response control group COVID-19 COVID-19 vaccine cytokine dose flow cytometry functional healthy control healthy controls humoral Immunosuppressant immunosuppressants interferon-γ Messenger RNA mRNA Necrosis Neutralization assay neutralizing antibody not different Patient patients patients treated performed Pfizer-BioNTech proportion Responder response rituximab RTX SARS-CoV-2 peptide SARS-CoV-2 spike peptide shown staining T cell response the healthy the vaccine time treated vaccine dose [DOI] 10.1002/art.42058 PMC 바로가기 [Article Type] Article
Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in patients with haematological diseases treated with anti-CD20 antibodies: An observational study항-CD20 항체로 치료한 혈액 질환 환자에서 BNT162b2 및 mRNA-1273 COVID-19 백신의 체액 반응 및 안전성: 관찰 연구Observational Study Published on 2022-06-012022-09-12 Journal: British Journal of Haematology [Category] MERS, 임상, 진단, [키워드] Abstract anti-CD20 BNT162b2 COVID-19 disease haematological disorders Humoral response mRNA-1273 mRNA-1273 COVID-19 vaccine obinutuzumab patients with haematological rituximab treated [DOI] 10.1111/bjh.18151 PMC 바로가기 [Article Type] Observational Study
Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series코로나바이러스 질병 2019 환자의 렘데시비르 항-CD20 단일클론항체 치료: 사례 시리즈Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: Infection [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료제, [키워드] administration anti-CD20 Anti-CD20 antibodies anti-CD20 treatment antiviral therapy approved baseline baseline data benefit Case series case sery Clinical improvement Clinical outcome consecutive patient control group convalescent plasma COVID-19 COVID-19 patient COVID-19 symptoms Diagnosis died disease course Follow-up healthcare Infection lack majority malignancy management median monoclonal not performed one patient outcomes pandemic Patient patient population patients patients died patients treated PCR performed Randomized controlled trial Randomized controlled trials reductions reductions in relapsing Remdesivir reported rituximab SARS-CoV-2 Study design symptom onset Symptoms These data Treatment two patients Viral viral clearance viral loads [DOI] 10.1007/s15010-022-01821-y PMC 바로가기 [Article Type] Randomized Controlled Trial
SARS-COV-2 vaccine responses in renal patient populations신장 환자 집단에서 SARS-COV-2 백신 반응Multicenter Study Published on 2022-05-312022-09-12 Journal: BMC Nephrology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Adenovirus adjusted odds ratio antibody Antibody Response Autoimmune Autoimmune disease AZ vaccine Breakthrough infection CKD conducted COVID-19 dialysis group healthy control healthy controls Immunosuppressed Immunosuppression increased risk kidney transplant Lower Luminex assay MMF mRNA multicentre multiplex mycophenolate occurred Oxford-AstraZeneca Patient patient population patients Pfizer Population positive response receiving recipients recruited reduced renal repeated response response to vaccination rituximab SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 vaccine second dose Spike protein Transplant trials vaccination Vaccine vaccine doses vaccine response were excluded were measured [DOI] 10.1186/s12882-022-02792-w PMC 바로가기 [Article Type] Multicenter Study
Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal AntibodiesArticle Published on 2022-05-302023-07-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), [키워드] anti-CD20 monoclonal antibodies COVID-19 covid-19 relapse rituximab SARS-COV-2 infection [DOI] 10.1093/cid/ciab700
Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohortBrief Report Published on 2022-05-042024-09-04 Journal: Clinical Rheumatology [Category] 대상포진, [키워드] ANCA Granulomatosis with polyangiitis induction maintenance Microscopic Polyangiitis rituximab [DOI] 10.1007/s10067-022-06192-1 PMC 바로가기 [Article Type] Brief Report
Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab리툭시맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 백신 접종에 대한 혈청학적 반응과 관련된 요인Article Published on 2022-05-022022-09-12 Journal: JAMA Network Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accumulated age analyzed angiotensin-converting enzyme 2 Anti-RBD IgG anti-receptor-binding domain Anti-spike anti-Spike IgG antibodies antibody B cells B-cell binding antibody CD19+ CD4+ T-cell CD8+ T-cell cellular response cohort study conducted COVID-19 infection Cutoff cutoff value Diagnosis disease dose Factor first vaccination Follow-up greater identify IgG IgG antibodies Immunoglobulin interferon gamma median monoclonal antibody Multiple multiple sclerosis Neutralizing outcome outcomes Patient patients evaluated peptide pool positive response positive test result proportion prospective cohort study quantitation RBD reached response rituximab SARS-CoV-2 sclerosis serological response spot-forming unit T-cell Response the median Treatment university hospital vaccination vaccine response Vaccines were assessed were measured women [DOI] 10.1001/jamanetworkopen.2022.11497 PMC 바로가기 [Article Type] Article
Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases류마티스 질환이 있는 283명의 프랑스 코호트에서 SARS-CoV-2에 대한 체액 반응의 체계적인 평가Article Published on 2022-05-012022-09-11 Journal: Joint bone spine [Category] COVID19(2023년), SARS, 치료기술, 치료법, [키워드] anti-S Arthritis Asymptomatic Cohort COVID-19 Descriptive analyses Descriptive analysis detect diagnosis of COVID-19 diagnosis of SARS-CoV-2 DMARDs form French humoral IgG infected patients Infection infliximab nucleocapsid protein outpatient clinic Paris Patient patients performed proportion Protein rheumatic disease Rheumatic diseases Rheumatoid rheumatoid arthritis rituximab RTX SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections screened serological test serology Seroprevalence significant difference Spike protein spondyloarthritis symptomatic the SARS-CoV-2 the Spike [DOI] 10.1016/j.jbspin.2021.105312 PMC 바로가기 [Article Type] Article
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients벨리무맙 및 리툭시맙 수혜자에서 COVID-19 백신 접종 후 높은 T 세포 반응률Article Published on 2022-05-012022-09-11 Journal: Journal of autoimmunity [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] absence All the patient all the patients analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody Autoimmune diseases B cell B cells B-cell Belimumab caused circulating comparable completion complex Concentration consecutive patient Control COVID-19 COVID-19 vaccination COVID-19 vaccine detectable anti-SARS-CoV-2 antibodies detectable anti-SARS-CoV-2 antibody diagnostic evaluate evaluated exposure to healthcare personnel immune response immune responses immunogenicity indicate interferon Lupus material median mRNA vaccination mRNA vaccine mRNA vaccines neutralizing capacity Participants Patient patients patients treated positive pseudoviruses RBD receiving recipient recruited retention rituximab RTX SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 pseudoviruses SARS-CoV-2 vaccination significantly lower strain systemic autoimmune disease Systemic autoimmune diseases T cell T-cell Response tested the antibodies the patient therapy Total treated Treatment vaccination Vaccine virus virus-specific cellular immunity [DOI] 10.1016/j.jaut.2022.102827 PMC 바로가기 [Article Type] Article